-
Valeant Pharmaceuticals Announces License Of ACZONE Gel 5% In Canada
Tuesday, February 8, 2011 - 9:09am | 70Valeant Pharmaceuticals International, Inc. (NYSE: VRX) today announced that its subsidiary, Biovail Laboratories International SRL, has entered into an agreement to license the Canadian rights to ACZONE Gel 5%, a topical formulation of dapsone used in the treatment of acne vulgaris, from Allergan...
-
A Peek Into The Market Before The Trading Starts
Tuesday, February 8, 2011 - 8:44am | 514Pre-open movers US stock futures are flat this morning after China's central bank raised interest rates. Futures on the Dow Jones Industrial Average rose 9 points to 12,117 and S&P 500 futures dropped 0.60 point to 1,315. Nasdaq 100 futures gained 0.50 point to 2,345.50. A Peek Into Global...
-
Roth Capital Opens AMRN With Buy
Tuesday, February 8, 2011 - 7:39am | 51Analysts at Roth Capital initiate coverage of Amarin Corporation plc (NASDAQ: AMRN) with a “buy” rating. The target price for AMRN is set to $13. AMRN shares fell 0.46% to close at $8.59 yesterday. More Analyst Ratings here
-
US Stock Futures Flat As China's Central Bank Lifts Interest Rates
Tuesday, February 8, 2011 - 7:27am | 329US stock futures are flat this morning after China's central bank raised interest rates. Futures on the Dow Jones Industrial Average rose 5 points to 12,113.00 and S&P 500 futures dropped 0.20 point to 1,315.60. Nasdaq 100 futures gained 0.50 point to 2,345.50. US stocks closed higher, with...
-
Teva Reports Q4 EPS of $1.25
Tuesday, February 8, 2011 - 6:53am | 58Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) reports its Q4 non-GAAP EPS at $1.25, versus the consensus of $1.28. TEVA reports its Q4 revenue at $4.42 billion, versus the consensus of $4.64 billion. TEVA shares dropped 2.89% to $53.39 in pre-market trading. Read more from Benzinga's Company...
-
Elan Reports Q4 Loss of $0.09 per share
Tuesday, February 8, 2011 - 6:37am | 60Elan Corp (NYSE: ELN) reports its Q4 loss at $0.09 per share, versus the expected loss of $0.04 per share. ELN reports its Q4 revenue at $308.9 million, versus the consensus of $286.57 million. ELN shares gained 1.76% to $6.95 in pre-market trading. Read more from Benzinga's Company news.
-
Elan Corporation Posts Mixed Results (ELN)
Tuesday, February 8, 2011 - 6:02am | 215Dublin, Ireland-based biotech company Elan Corporation (NYSE: ELN) released financial results on Tuesday morning that missed Wall Street earnings estimates, while beating revenue expectations. Elan Corporation announced that its 4th quarter net loss narrowed to $52.2 million, or 9 cents per share,...
-
Teva Pharmaceutical Industries Misses Estimates Despite Growth (TEVA)
Tuesday, February 8, 2011 - 5:44am | 257Petach Tikva, Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) on Tuesday morning released financial results that failed to meet Wall Street expectations. Teva Pharmaceutical Industries reported that its 4th quarter net income climbed to $771 million, or 85 cents per share, up from $379...
-
Top 4 Small-Cap Stocks In The Real Estate Development Industry With The Highest Cash (AFP, CTC, BXG, COR)
Tuesday, February 8, 2011 - 5:39am | 143Below are the top small-cap real estate development stocks on the NYSE, the NASDAQ and the AMEX in terms of cash. United Capital Corporation (AMEX: AFP) had $147.61 million in total cash for the latest quarter. AFP's total debt for the same period amounted to $32.15 million. IFM Investments Limited...
-
Earnings Scheduled For February 8 (CVH, DIS, MNI, MFE, TEVA, PBI, AVP, SLE, ETR, TTWO)
Tuesday, February 8, 2011 - 5:31am | 270Coventry Health Care Inc (NYSE: CVH) is expected to post its Q4 earnings at $0.88 per share on revenue of $3.01 billion. Walt Disney (NYSE: DIS) is projected to report its earnings at $0.56 per share on revenue of $10.52 billion in first quarter. McClatchy Co (NYSE: MNI) is expected to post its Q4...
-
Glaxo Set To Pay Out After Diabetes Drug Linked To Heart Attacks (GSK)
Monday, February 7, 2011 - 1:48pm | 186GlaxoSmithKline (NYSE: GSK) is set to pay $250 million to settle Avandia death lawsuits according to Bloomberg. The litigation is based upon the Avandia diabetes drug that is linked to claims of increased heart-attack and stroke risks. The total sum looks to settle about 5,500 claims at an average...
-
FDA Approves Labeling Update for REYATAZ Capsules to Include Data Supporting the Recommended Adult Dose for HIV-1 Infected Pregnant Women
Monday, February 7, 2011 - 11:40am | 127Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the labeling for REYATA to include dose recommendations in HIV-infected pregnant women. In HIV combination therapy, treatment with the recommended adult dose of...
-
Deutsche Bank Maintains Buy on Medicis Pharmaceutical (MRX)
Monday, February 7, 2011 - 11:15am | 111Deutsche Bank is out with its report today on Medicis Pharmaceutical (NYSE: MRX), maintaining Buy. In a note to clients, Deutsche Bank writes, "The outlook for Medicis's flagship Solodyn franchise has improved significantly over the past six months – based on a strong switch thus far to the new...
-
Citi Comments On St. Jude Medical Following Investor Meeting
Monday, February 7, 2011 - 10:40am | 199St. Jude Medical's (NYSE: STJ) investor day on Friday went into overtime as significant time was spent on pipeline areas outside of core CRM. In Citi's view, the company's long-term pipeline assumptions is very optimistic and harkens back to BSX's 2005 investor day presentation. Management made a...
-
AstraZeneca and Targacept Initiate Phase 2b Clinical Trial of TC-5214
Monday, February 7, 2011 - 9:58am | 112AstraZeneca (NYSE: AZN) and Targacept, Inc. (Nasdaq: TRGT) today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a “switch” monotherapy treatment for patients with major depressive disorder who do not respond adequately to initial antidepressant therapy...